Adagene Inc. (ADAG)
ADAG trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/0001104659-26-038612-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ADAG on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | China |
| IPO year | 2021 |
| SEC CIK | 0001818838 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.7M |
| Net income | -$17.6M |
| Operating income | -$21.4M |
| Net margin | -229.6% |
| Operating margin | -279.5% |
| Revenue growth | +7332.8% |
| Cash | $74.5M |
| Total assets | $78.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 13.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-01 |
| Cash and burn | $74.5M cash; operating cash flow -$3.9M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-04-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers Zhong Tian LLP, Shanghai, China | PCAOB Form AP 2026-04-29 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $162K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $7.7M | -$17.6M | -$15.7M | $74.5M | $1.8M | $7.7M | 20-F 2026-04-01 |
| FY 2024 2024-12-31 | $103K | -$33.4M | -$29.7M | $85.2M | $13.3M | $103K | 20-F 2026-04-01 |
| FY 2023 2023-12-31 | $18.1M | -$18.9M | -$28.5M | $109.9M | $17.7M | $18.1M | 20-F 2026-04-01 |
| FY 2022 2022-12-31 | $9.3M | -$80.0M | -$48.6M | $143.8M | $17.0M | $9.3M | 20-F 2025-03-24 |
| FY 2021 2021-12-31 | $10.2M | -$73.2M | -$43.4M | $174.4M | $4.4M | $10.2M | 20-F 2024-03-29 |
| FY 2020 2020-12-31 | $701K | -$42.4M | -$28.5M | $75.2M | $4.1M | $701K | 20-F 2023-04-28 |
| FY 2019 2019-12-31 | $480K | -$16.4M | -$18.2M | $92.5M | $1.8M | $480K | 20-F 2022-04-26 |
| FY 2018 2018-12-31 | $1.5M | -$15.3M | -$14.3M | $16.1M | No debt tags | $1.5M | 20-F 2021-04-28 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-02 |
| Latest annual report | 20-F | 2026-04-01 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-09 |
Source: SEC EDGAR submissions feed, 192 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.5% |
| 1 month | -30.5% |
| 3 months | -54.0% |
| Year to date | -9.5% |
| 1 year | -5.0% |
| From 52-week high | -64.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLLS | Cellectis S.A. | $1.04 | -11.86% | $104.5M |
| DERM | Journey Medical Corporation | $3.70 | -14.55% | $104.5M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| ORGO | Organogenesis Holdings Inc. | $0.8031 | -0.86% | $104.2M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
| UNCY | Unicycive Therapeutics Inc. | $3.70 | +4.23% | $103.1M |
| CUE | Cue Biopharma Inc. | $14.10 | -12.53% | $102.4M |
| OGI | Organigram Global Inc. Common Shares | $0.7240 | -12.62% | $102.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier